Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

731.59 +6.72 (+0.93%)
Streaming Delayed Price Updated: 10:06 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Meta Platforms, AMD Lead 10 Stocks Showing This Bullish Action
Several leading stocks are finding support around the 10-week line, creating potential buying opportunities. 
Via Investor's Business Daily
Buy Amazon Stock Now for Continued Growth and Diversification
Year to date, Amazon's share price is up 20%, nearly double the 11% gain in the benchmark S&P 500 index. Over the last 12 months, Amazon stock has gained 75%. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Could Viking Therapeutics Stock Be a Millionaire Maker?
There is a plausible path for this biotech stock to make some investors millionaires. 
Via The Motley Fool
Is It Too Late to Buy Eli Lilly Stock?
There's more to the Lilly story than just excellence in one treatment area. 
Via The Motley Fool
Top Stock Reports For Apple, Nvidia & Eli Lilly
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., NVIDIA Corporation, and Eli Lilly and Company. 
Via Talk Markets
What Analysts Are Saying About Eli Lilly and Co Stock
Via Benzinga
Eli Lilly and Co's Options: A Look at What the Big Money is Thinking
Via Benzinga
Missed the "Magnificent Seven"? Try Buying These 3 Forever Stocks Instead
All three companies have very long runways for growth ahead. 
Via The Motley Fool
Meet The "Magnificent Seven" of Healthcare Stocks
The tech sector doesn't have a monopoly on magnificent corporations. 
Via The Motley Fool
2 Top Biotech Buyout Candidates
Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be... 
Via Talk Markets
Have $1,500? 2 Top Growth Stocks to Buy Right Now for 2024 and Beyond
Great companies in steadily growing industries can deliver enviable returns through the years. 
Via The Motley Fool
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects. 
Via The Motley Fool
Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Nektar Therapeutics commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin, in patients with severe to very severe alopecia areata, a disease-causing patchy hair... 
Via Talk Markets
Topics Lawsuit
Exposures Financial Legal
The 3 Best Biotech Stocks to Buy in Q2 2024
Biotech can be a risky industry for investors, but we've done the legwork for you with these three biotech stocks for Q2. 
Via InvestorPlace
Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1?
The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried about the sustainability of the uptrend. 
Via Benzinga
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
Here's How Much You Would Have Made Owning Eli Lilly and Co Stock In The Last 5 Years
Via Benzinga
Eli Lilly vs. Berkshire Hathaway: Which Stock Will Become the Next Member of the $1 Trillion Club?
Don't assume that because Berkshire is worth nearly $900 billion, it's sure to get to $1 trillion first. 
Via The Motley Fool
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. 
Via Investor's Business Daily
Exposures Product Safety
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 
Via The Motley Fool
Prediction: This Will Be the Next "Magnificent Seven" Stock
This particular company's growth is set to take off... 
Via The Motley Fool
US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar
The Japanese yen fell Wednesday to a 34-year low against the dollar, which is a boon for exporters, but imports are more expensive. 
Via Benzinga
The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months
Let's review what Wall Street analysts believe are potentially the stocks to double over the next 12 months. 
Via InvestorPlace
Krispy Kreme-McDonald's Deal Spikes Insulin Stock Interest: 'We're About To Cash In On The Aftermath'
Krispy Kreme's partnership with McDonald's has led to a surge in stock prices. Investors are turning to insulin stocks to capitalize on the growing demand. 
Via Benzinga
Obesity Drug Landscape Has A Contender From Biohaven, CEO Highlights Different Approach Amid Stiff Competition From Novo Nordisk, Eli Lilly
Biohaven's approach to combat obesity. Learn about their experimental drug taldefgrobep alfa (t-alpha), targeting muscle growth regulation for effective weight loss. CEO Vlad Coric discusses its... 
Via Benzinga
Viking Surges After Weight-Loss Pill Tops Expectations In Just 28 Days
People lost more weight than the company expected over a 28-day study. 
Via Investor's Business Daily
Tuesday Talk: Big-Tech Under Attack
On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs. 
Via Talk Markets
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
All three of these high-flying stocks could have more room to run. 
Via The Motley Fool
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall Street
Find out why investment banks up and down Wall Street have big expectations for these stocks. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.